1 2	Biomonitoring of perfluoroalkyl and polyfluoroalkyl substances (PFAS) from the Survey of the Health of Wisconsin (SHOW) 2014-2016 and comparison with the National Health and
3	Nutrition Examination Survey (NHANES)
4	
5	Amy Schultz PhD MS ¹ , Noel Stanton MS ² , Rachel Pomazal ¹ , Meshel Lange ² , Roy Irving PhD ³ ,
6	Jonathan Meiman PhD ³ , Brandon Shelton ² , Kristen CM Malecki PhD MPH ^{1,4}
7	
8	¹ Survey of the Health of Wisconsin (SHOW), University of Wisconsin Madison ² Wisconsin
9	State Lab of Hygiene (WSLH) ³ Wisconsin Department of Health Services ⁴ University of Illinois
10	at Chicago School of Public Health
11	
12	Corresponding Author: Amy Schultz PhD MS aaschultz4@show.wisc.edu
13	
14	Funding: Funding for SHOW comes from the Wisconsin Division of Public Health, the
15	Wisconsin Partnership Program (PERC) Award (223 PRJ 25DJ), the National Institutes of
16	Health's Clinical and Translational Science Award (5UL 1RR025011), and the National Heart
17	Lunch and Blood Institute (1 RC2 HL101468) and a core grant to the Center for Demography
18	and Ecology at the University of Wisconsin-Madison (P2C HD047873).
19	

20 Abstract

- 21 **Background:** Per- and polyfluoroalkyl substances (PFAS) are a growing class of manufactured
- 22 chemical compounds found in a variety of consumer products. PFAS have become ubiquitous in
- the environment and were found in many humans sampled in the United States (U.S.). Yet,
- significant gaps in understanding statewide level exposures to PFAS remain.
- 25 **Objective:** The goals of this study are to establish a baseline of exposure at the state level by
- 26 measuring PFAS serum levels among a representative sample of Wisconsin residents and
- 27 compare to United States National Health and Nutrition Examination Survey (NHANES).
- 28 Methods: The study sample included 605 adults (18+ years of age) selected from the 2014-2016
- sample of the Survey of the Health of Wisconsin (SHOW). Thirty-eight PFAS serum
- 30 concentrations were measured using high-pressure liquid chromatography coupled with tandem
- 31 mass spectrometric detection (HPLC-MS/MS) and geometric means presented. Weighted
- 32 geometric mean serum values of eight PFAS analytes from SHOW were compared to U.S.
- national levels from the NHANES 2015-2016 sample (PFOS, PFOA, PFNA, PFHxS, PFHpS,
- PFDA, PFUnDA), and the 2017-2018 sample for Me-PFOSA, PFHPS using the Wilcoxon rank sum test.
- **Results:** Over 96% of SHOW participants had positive results for PFOS, PFHxS, PFHpS,
- 37 PFDA, PFNA, and PFOA. In general, SHOW participants had lower serum levels across all
- 38 PFAS when compared to NHANES. Serum levels increased with age and were higher among
- 39 males and whites. These trends were seen in NHANES, except non-whites had higher PFAS
- 40 levels at higher percentiles.
- 41 Significance: Wisconsin residents may have a lower overall body burden of some PFAS
- 42 compounds compared to those seen by a nationally representative sample. Additional testing and
- 43 characterization may be needed in Wisconsin, particularly among non-whites and low
- 44 socioeconomic status, for which the SHOW sample had less representation compared to
- 45 NHANES.
- 46
- Keywords: Exposure assessment, PFAS, Per and Poly fluoroalkyl substances, population-based
 Keywords: Exposure assessment, PFAS, Per and Poly fluoroalkyl substances, population-based
- 49 **Impact Statement:** The present study conducts biomonitoring of 38 PFAS in the state of
- 50 Wisconsin and suggests that while most residents of Wisconsin have detectable levels of PFAS
- 51 in their blood serum, they may have a lower body burden of some PFAS compared to a
- nationally representative sample. Older adults, males, and whites may have a higher body burden
- of PFAS relative to other groups both in Wisconsin and the wider United States.
- 54 55

1. Introduction

- 56 Per- and polyfluoroalkyl substances (PFAS) are a large family of manufactured, or human-made, 57 fluoringted compounds produced for a variety of consumer products. PEAS are known as leaves
- 57 fluorinated compounds produced for a variety of consumer products. PFAS are known as legacy
- chemicals because of their long half-life and ability to accumulate in the environment, as well as in animal and human blood serum and tissue [1-2]. The water and oil repellent properties of
- 59 in animal and human blood serum and tissue [1-2]. The water and oil repellent properties of 60 PEAS make them desirable for use as flows retardants and other common consumer products
- 60 PFAS make them desirable for use as flame retardants and other common consumer products [2].
- 61 PFAS are highly stable compounds that not only repel water, oils, and lipids, but bind to proteins
- 62 [3], and their strong carbon-fluorine bonds do not readily degrade. Therefore, some PFAS
- 63 compounds can remain within all trophic levels for years or decades [4].
- 64

The stability of these compounds makes mitigation and removal of PFAS from the environment

- 66 challenging. Environmental contamination sites have been identified for PFAS, which often
- arise from industrial production or agricultural practices using contaminated fertilizer [5]. Over
- time, PFAS leach into groundwater, surface waters, and soil. Major exposure pathways for PFAS
- 69 in humans include consumption of contaminated food, especially fish and red meat [6]. Other
- sources of human exposure to PFAS include drinking water, contact with consumer products,
- 71 and ingestion of dust particles [2].
- 72

73 Due to the widespread use of PFAS, recent environmental assessments have found them to be

- vubiquitous in the environment and in humans [7]. The U.S. Centers for Disease Control (CDC)
- biomonitoring of PFAS in the U.S. general population found nearly all the n=7991 U.S. residents
- tested via the 2011-2018 NHANES survey had detectable levels of one or more of the most
- studied long-chain PFAS: PFOA, PFOS, PFHxS, and PFNA [8]. This raised public health
- concerns, especially as PFAS research finds more associations between PFAS exposure and
- adverse human health effects [9]. Exposure to PFAS has been associated with cancer [10],
- 80 higher cholesterol [11], liver enzyme changes [12], lower infant birth weight [13], decreased
- pediatric vaccine response [14], increased risk of gestational hypertension or pre-eclampsia [15],
- and immune suppression [16].
- 83

While PFOS and PFOA went largely unregulated for decades, in 2002 the U.S. Environmental
 Protection Agency (EPA) began to regulate PFAS, requiring manufacturers to notify the EPA of

- the manufacture or import of 13, and later 75, of the compounds [17]. Long-chain PFAS are still
- used in imported products from developing countries [18,19]. In June 2022, the EPA set a non-
- enforceable lifetime health advisory for PFOS and PFOA in drinking water to 0.02 and 0.004
- 89 parts per trillion, respectively [20]. A handful of states, including Wisconsin, have adopted the
- 2016 standard as the statewide regulatory standard for at least one PFAS compound [21]. This is
- a rapidly evolving regulatory landscape, with some states making recommendations more
- stringent than the EPA standard, and others making no recommendations at all [21]. However,
- there are an estimated 4000 PFAS compounds [17] produced by industry, no biomonitoring or
- epidemiological research on the vast majority of PFAS. Although long-chain PFASs (PFOA and
- 95 PFAS) have been phased out of production in the U.S. and Canada, they are replaced by short-
- 96 chain PFAS in industrial production. Additional biomonitoring and research are needed to
- 97 understand how short-chain PFAS affect human health [22].
- 98

99 CDC biomonitoring of PFAS in the U.S. general population, and several other biomonitoring studies have emerged in the U.S. over the last decade. Little biomonitoring yet to be seen in the 100 Upper Midwest and central region of the U.S. [23-27]. With NHANES data, the CDC established 101 baseline exposure data for PFAS in the U.S., but the scale of the survey lacks the granularity 102 needed to understand PFAS within smaller regions and demographic strata at the state or local 103 level. The other community-based and localized biomonitoring studies to-date are not sampled in 104 105 such a way to provide representation of PFAS exposure across an entire state. This study begins to fill this data gap by providing baseline PFAS levels representative of residents in the state of 106 Wisconsin. The study uses serum samples from The Survey of the Health of Wisconsin (SHOW) 107 108 cohort, the only statewide representative health survey in the U.S. modeled after NHANES.

109

110 In Wisconsin, PFAS have been found in groundwater supplies exceeding health-based

recommendations [28]. Not only are there several contamination sites in Wisconsin, including

the Marinette and Peshtigo areas in Marinette county due to production and testing of aqueous

- film-forming foams (AFFF) [29], but it's history in paper production and known PCB and
- 114 mercury contamination water ways from paper mills [30-32], in conjunction with agricultural use
- of wastewater sludge on crop fields, provide a landscape upon which residents may be at risk of
- PFAS exposure [33-34]. PFAS has been detected in not only groundwater, but in milk raised and
- produced in Wisconsin, the second largest dairy producing state [33]. Eighteen different PFAS
- 118 compounds were detected in well samples in Madison, Wisconsin in domestic, municipal, and
- agricultural wells [35]. Furthermore, Wisconsin's variable geography (forested, agricultural, and varying levels of urbanicity) and demographics are reasonably comparable to that of the broader
- 120 Varying levels of urbanicity) and demographics are reasonably comparable to that of t 121 United States in age structure, gender, and race [36].
- 122
- 123 The Wisconsin State Laboratory of Hygiene (WSLH) developed a new method to detect PFAS
- compounds at lower concentrations which increases the number of compounds available for
- assessment than have been used by many previous biomonitoring studies. In this study, we first
- examined an expanded list of PFAS compounds analyzed them using high-pressure liquid
- 127 chromatography coupled with tandem mass spectrometric detection (HPLC-MS/MS) and, where
- we were able to, compared SHOW PFAS serum levels to those PFAS serum levels of a
- nationally representative sample of the United States (NHANES). While other studies have
- 130 drawn comparisons to NHANES PFAS levels, to our knowledge, no other statewide
- 131 representative samples have compared PFAS levels to NHANES.
- 132

133 **2.** Methods

134 **2.1 Survey of the Health of Wisconsin (SHOW)**

Survey data and biospecimens came from the 2014-2016 Survey of the Health of Wisconsin (SHOW) statewide representative sample of adults ages 18 and older (n=1957). Details on the SHOW sampling frame, recruitment, and methods are described elsewhere [37]. In brief, the SHOW 2014–2016 cohort was designed as a three-year sample. A three-stage cluster-sampling approach was employed. One county per strata was randomly selected within the strata of county mortality rates, followed by random selection of census block groups by poverty status strata. Then 30–35 residential households were randomly selected via US postal service listings.

- 142 Housed within the Department of Population Health Sciences at the University of Wisconsin-
- 143 Madison, SHOW conducts statewide population–based recruitment and longitudinal follow-up of
- a representative sample of state residents SHOW is unique in that it is the only statewide
- 145 household-based examination survey in the United States and offers an abundance of survey and
- 146 physical measurement data upon which to characterize PFAS exposure within our sample.
- 147 Modeled after the CDC's NHANES, its survey data includes demographics (age, gender,
- education, income, race), behaviors (smoking, diet), occupation (military service, firefighter),
- housing (type and age of residence), drinking water characteristics (private well vs. municipal,
- depth of private well, consumption pattern, treatment/filter use), diet (fish, dairy) and chronic
- health conditions (cancer, diabetes, hypertension, obesity). In addition, participant households
- span rural, urban and suburban settings and are geocoded to allow for linkages to contextual
- environmental data, including potential PFAS sources (landfills, industrial and municipal
- 154 wastewater facilities, agricultural fields).

155 Households are randomly selected from commercially available US Postal Service residential

- address listings using a random probability-based sampling procedure and SHOW trained
- 157 interviewers conduct in-home visits upon which they gather health information via computer
- assisted personal interview (CAPI). Participants also complete a self-administered paper
- 159 questionnaire. Following an in-home visit, participants visit a collection site near their home
- where phlebotomists measure blood pressure, weight, height, waist and hip circumference,
- respiratory function, and collect venous blood and urine samples. Several tubes of venous blood (about 55–60 ml in total) are immediately processed for serum and plasma, aliquoted into
- 163 cryovials and frozen at -80C. SHOW participants consent to the use of biospecimens for
- 164 unspecified research. The core SHOW study and this study is approved by the University of
- 165 Wisconsin Health Sciences Institutional Review Board and all biosecurity and institutional safety
- 166 procedures are HIPAA compliant.
- 167 For this study, a subset of (n=605) participants were selected at random from SHOW's 2014–
- 168 2016 statewide representative sample. For this retrospective sample analysis, a single random
- sample of adults 18 + (n=50; stratified by race, sex, age), was pulled from each of 12 counties
- representing each of 5 health regions in the state. Only individuals with stored serum were
- included when selecting the study sample. This allows for the assessment of historic PFAS
- exposures across Wisconsin and accelerates the ability to observe time-dependent trends in
- exposures when prospective sampling is performed. An additional sample was pulled per health
- region as substitution in case any samples were not viable for PFAS analyses. Serum samples
 were extracted from SHOW's freezer and sent to the Wisconsin State Laboratory of Hygiene on
- 175 were extracted from SHOW's freezer and sent to the wisconsin 176 dry ice for PFAS analyses.

177 2.3 PFAS Sample Analysis

- 178 The PFAS analyses were performed by the Wisconsin State Lab of Hygiene (WSLH) using high-
- 179 pressure liquid chromatography coupled with tandem mass spectrometric detection (HPLC-
- 180 MS/MS). The 38 PFAS compounds tested were selected based on several considerations,
- including, (1) cover the spectrum of compounds to look for class-specific bioaccumulation, (2)
- include compounds most often used in products and tested by CDC in NHANES, (3) include
- both short and long chain PFAS to assess differences by type, (4) include emerging compound
- 184 classes for which we have little data, (5) consider potential toxicity estimates, and (6) limited by
- 185 the availability of suitable materials to assure reliable measurement.
- 186 The WSLH test method was adapted primarily from a method developed by Minnesota Dept. of
- 187 Public Health [38], with elements from CDC Method 6304.08 [39], the New York State Dept. of
- Health [40], and the Michigan Dept. of Community Health [41]. Several of these documents arelaboratory manuals, some shared privately between colleagues. Sample preparation involved
- spiking aliquots of serum with an isotopically labeled PFAS mixture. Acetonitrile was added to
- precipitate proteins, followed by vortex mixing. Samples were then centrifuged, the supernatant
- transferred to a 96-well plate, and evaporated to a volume of 100-200 mL.
- 193 Prepared samples were injected on an Agilent 1290 Infinity UPLC (Santa Clara, CA) equipped
- 194 with a BEH C18 1.7mm 2.1X50mm Column (Waters, Milford, MA). Good chromatographic
- separation was achieved using a reverse phase gradient, with a 20 minute run time at 45° C.
- 196 Sample detection and quantification was achieved with a Sciex 4500 MS/MS system (Toronto,

197 CA), employing multiple reaction mode (MRM) scanning with negative polarity turbospray

198 ionization. Q1 and Q3 masses, declustering Potential (DP), collision energy (CE) and collision

199 cell exit potential (CXP) values for each MRM transition were optimized by parameter ramping

- 200 experiments with direct standard solution infusion to the source. Sciex Analyst version 1.6.3 was
- used for data acquisition and results calculation. 201

Method quality control characteristics included a method blank and seven standard linear 202

calibration standards (r > 0.995). Standards were verified using a second source material. 203

204 Analytical signal/noise for S_1 was required to be >10. Ion confirmation ratio for samples was

205 required to fall within +30% of the mean ratio of the standards, with exceptions for PFOS,

FOSA, PFDA, PFNS, 11Cl-PF3OUdS, PFHxA, PFTrDA, PFDS, PFTeDA, and 8:2 diPAP, 206

207 which were widened to +40% based on poor confirmation ion sensitivity. Method detection

limits varied considerably by compound, as did the upper quantification limits, but compare 208

209 favorably with NHANES quantification thresholds for those compounds. Three levels of 210 analytical controls were measured in every analytical run, and acceptable control values

bracketed all test samples. Method validation also included precision, analytical measurement 211

range, and spike recovery assessment. Additional details on the analytical method area and 212

observations on compounds not comparable with NHANES are in preparation. 213

214 2.4 National Health and Nutrition Examination Survey (NHANES)

NHANES is an ongoing national cross-sectional survey administered by the National Center of 215

Health Statistics (NCHS) within the CDC. NHANES uses a multistage cluster sampling 216

approach to examine a study population that is representative of the United States' non-217

218 institutionalized population. Blood samples are taken from all NHANES participants 12 years of

age and older. Approximately 2,000 of these samples were analyzed for several PFAS 219

compounds in each cycle. The NHANES 2015-2016 sample intentionally oversamples Hispanic, 220

Non-Hispanic black, Non-Hispanic Asian, Non-Hispanic white and others at or below 185 221

percent of the Department of Health and Human Services (HHS) poverty guidelines, and Non-222

Hispanic white and other people aged 80 years and older. NHANES releases publicly available 223

224 laboratory and demographic data on these participants. Education and smoking status for

225 adolescents (age 12-19) is considered sensitive data and not included in public use datasets.

Documentation for NHANES data includes detailed laboratory methods [42]. For this study, 226 SHOW study sample PFAS serum levels were compared with those from the National Health

227

228 and Nutrition Examination Survey (NHANES) 2015-2016 sample (n=1829) for all

corresponding samples. However, given that NHANES did not sample the entire suite of 229

230 compounds in this study, the 2017-2018 (n=1862) samples were compared for select compounds

(ME-PFOSA and PFHPS). 231

2.5 Demographics 232

Self-reported demographics data for gender, age, race/ethnicity, highest education level attained, 233

234 and income were collected by CAPI. Smoking status data were obtained through a self-

235 administered questionnaire (SAQ) for the Wisconsin Sample and personal interview for

NHANES. Income/poverty ratio was calculated by dividing the midpoint of reported household 236

income range by HHS poverty guidelines, which is calculated by the number of people supported 237

by that income [43]. Body mass index (BMI) (kg/m²) was calculated using WHO standards by 238

dividing measured height (cm) by 100, and squaring that value, and then dividing weight (kg) by

that value. SHOW and NHANES participants were stratified by gender, age, and race for

analysis of PFAS serum levels. Age groups were determined by generational changes (18-39, 40-

- 59, 60+), and race was grouped by non-Hispanic white and non-white. Minors in the NHANES
- samples were excluded from the final analysis.

244 **2.6 Statistical Analyses**

All statistical analyses were performed using SAS v9.4. All thirty-eight PFAS compounds were

- reported for SHOW using the LLOD available from the WSLH assays. However, only
- compounds analyzed in both SHOW and available in NHANES public use laboratory data were
- included in comparative data analysis, and only compounds with more than 15% positivity in the
 SHOW sample could be reliably compared to NHANES. Thus, weighted geometric means for 8
- 249 Show sample could be reliably compared to INFAILES. Thus, weighted geometric means for 8 250 PFAS compounds, as well as weighted geometric means for the 50^a, 75^a, 90^a, and 95^a percentiles
- and their corresponding 95% confidence intervals were calculated for SHOW and NHANES (see
- Table 2 for complete list of PFAS). The lower limit of detection (LLOD) for all compounds in
- NHANES was 0.1 ng/mL, with values lower than the LLOD set to 0.1 divided by the square root
- of 2, or approximately 0.07. The LLODs for SHOW participants were different from 0.1, but to
- 255 make direct comparisons, all PFAS compounds within SHOW were assigned the same LLOD as
- 256 NHANES for comparison analyses. Therefore, weighted geometric means differ for SHOW in
- the comparison tables with NHANES, when compared to findings from SHOW with the LLOD
- 258 from WSLH, unaltered to match NHANES.
- 259 PFOS and PFOA were analyzed as the sum of their linear and branched isomers, consistent with
- 260 NHANES methods. Data from minors ages 12-17 in the NHANES sample were used to validate
- 261 data analysis methods against published NHANES data tables, but minors were not included in
- the final analysis as all SHOW participants were over the age of 18. Geometric means of serum
- levels and corresponding 95% confidence intervals were calculated for all compounds and
- compared between SHOW and NHANES. Both NHANES and SHOW geometric means were
- calculated using subsample weights, and domains of gender, age, and race.
- 266 While overall and demographic strata comparisons of PFAS serum levels in SHOW vs.
- 267 NHANES are weighted, due to the different complexities of sampling in both SHOW and
- NHANES, unweighted comparisons of PFAS serum concentrations were evaluated using the
- 269 Wilcoxon rank-sum test to test difference. Compounds detected above the limit of detection in
- fewer than 50% of individuals were not included in further analysis comparisons with NHANES.
- 271
- 272 **3. Results**

273 **3.1 Study Sample**

- 274 Descriptive characteristics of the SHOW 2014-2016 subsample compared with NHANES 2015-
- 275 2016 and NHANES 2017-2018 samples are presented in Table 1. The SHOW study sample is
- comparable to NHANES in terms of gender and age distribution. There are slightly more females
- (50.7%) than males in SHOW; similar in NHANES (51.5-51.6%). The SHOW sample differs
- from NHANES most in terms of racial diversity. The SHOW consists of 81.3% non-Hispanic
- white, much higher when compared with NHANES where 62.3-62.9% are non-Hispanic white.
- 280 SHOW also had slightly more participants with >3 income to poverty ratio, fewer smokers, and

more with a BMI > 30 (Table 1). SHOW participants also tended to be more educated than

- 282 NHANES participants on average, with 27.1% of SHOW participants reporting high
- school/GED or less in SHOW, compared with 34.2% in NHANES.
- 284

285 **3.2 Prevalence of detectable serum PFAS levels**

- Table 2 depicts the detection limit and summary statistics for the number of positive results,
- 287 geometric mean, minimum and maximums for all 38 PFAS compounds. Nine of the 38 PFAS
- compounds were detected in at least 50% of SHOW participants (PFOS, PFOA, PFNA, PFHxS,
- 289 PFDA, PFHpS, PFUnDA, PFHpA, PFPeS) (Table 2). More than 96% of SHOW participants had
- serum levels above the lower limit of detection for six PFAS analytes, PFOS, PFOA, PFNA,
- 291 PFHxS, PFDA, and PFHpS with geometric mean values being 4.513, 1.196, 0.452, 1.138, 0.142,
- and 0.168 ng/mL, respectively. Eight PFAS compounds were below the limit of detection in
- 293 100% of the study sample (NMeFOSA, N-EtFOSE, 6:2 FTSA, PFTriA, PFODA, DONA,
- 294 PFMPA, PFMBA). SHOW participants had much higher levels of PFOS compared to other
- 295 compounds, with a whole sample geometric mean of 4.513 μ g/L (Table 2).
- 296

297 **3.3 PFAS Comparison of SHOW to NHANES by demographics**

- Table 3 depicts comparisons in geometric means and percentiles between the entire SHOW and
- 299 NHANES samples where LLOD has been adjusted for SHOW to match NHANES. Tables 4-6
- 300 (and supplementary tables 1-5) depict geometric means and percentiles comparing SHOW and
- 301 NHANES by demographic strata. Weighted geometrics means of PFAS serum levels were
- slightly higher among NHANES study sample compared to SHOW for PFOS, PFOA, PFNA,
- PFHxS, PFDA, and PFHPS. However, only PFOA and PFNA were statistically higher among
 NHANES compared SHOW (p <0.001). Most notable differences in weighted geometric means
- were seen for PFHPS, PFOA, and PFNA, where NHANES serum samples were 35.3%, 32.5%,
- and 31.1% higher than in SHOW, respectively. PFDA, PFOS, and PFHxS weighted geometrics
- mean serum levels were 14.3%, 10.2%, 7.0% higher in NHANES when compared to SHOW.
- 308 PFOS weighted geometric means (95% CI) were highest of all PFAS compounds in both study
- samples; 4.51 (4.18-4.87) in SHOW compared to 4.97 (4.71-5.25) in NHANES.
- 310
- 311 Serum levels increased with age in both SHOW and NHANES for all 6 PFAS compounds. In
- SHOW, 18–39-year-olds had a PFOS geometric mean of 3.13 (2.71-3.62) compared to 60+ year-
- olds 7.39 (6.72-8.31); whereas the 95th percentile was 8.80 (7.70-10.20) for 18–39-year-olds and
- 26.3 (21.8-30.5) for 60+ year-olds. Similar trends held for NHANES.
- 315
- In SHOW, males had higher serum levels of PFOS, PFOA, PFNA, PFHxS, and PFHPS than
- females; a difference in weighted geometric mean of 1.06, 0.1, 0.03, and 0.5 ng/mL,
- respectively. Levels did not differ by sex for PFDA; these trends by sex were seen in both the
- 319 NHANES and SHOW samples for all PFAS.
- 320
- 321 Weighted geometric mean serum levels were higher among whites (non-Hispanic) in SHOW and
- 322 NHANES for PFOA, PFOS, PFHxS and PFHPS when compared to nonwhites. These trends
- held in the 50-95th percentiles for SHOW, but for NHANES, these trends were opposite at the
- higher percentiles (90th and 95th) for PFHPS and PFOS. PFHPS was 40% higher, and PFOS was
- 325 20% higher, among nonwhites compared to whites (non-Hispanic) in NHANES at the 95th
- 326 percentile.

327

SHOW and NHANES samples were largely comparable for other PFAS compounds, (see Supp.
Tables 1-5), albeit low levels of detection were seen for both SHOW and NHANES for these
additional PFAS compounds.

331

332 **4. Discussion**

333 To our knowledge this is the first study to characterize PFAS serum levels among a statewide representative sample and compare levels to those of NHANES. This study expanded 334 biomonitoring to a panel of 38 PFAS compounds and detected concentrations in serum with 335 336 LLOD lower than many prior studies. The study leveraged the SHOW cohort, the only statewide adult cohort in the U.S. modeled after NHANES to provide baseline data for the state of 337 Wisconsin. Beyond NHANES, current understanding of human serum PFAS levels come from 338 specific sub-population cohorts (i.e. occupational, maternal-child cohorts) [23,44], high-risk or 339 340 localized communities near contamination [24-26]. While baseline PFAS levels are known at a national scale using NHANES, those data lack the granularity needed at the state level and 341 within subregions and strata in a state. SHOW's statewide cohort provides PFAS serum 342 343 prevalence for the state, and within subpopulations and communities, spanning different demographics, socio-economic backgrounds, and neighborhood environments. This study fills a 344 data gap and allows for identification of previously unknown high-risk areas or sub-populations 345

upon which researchers and state health officials can target additional biomonitoring and testing.

347

Among the 38 PFAS analytes tested, six were widely prevalent among SHOW; more than 96%

of SHOW participants had detectable serum levels of PFOS, PFOA, PFNA, PFHxS, PFDA, and

350 PFHpS. These findings align with what other studies have found. For example, Yu and

351 colleagues conducted statewide testing in New Jersey from remnant sera from clinical labs and

blood banks (n=1030) and of the 12 PFAS compounds tested, PFOA, PFNA, PFOS, and PFHxS

were the ones detected in over 99% of the study population with geometrics means greater than

 $0.5 \ \mu g/L \ [44]$. Even among high-risk or communities near contamination sites, the same PFAS

compounds were the most widespread, and with the highest geometric means. Among n=192
 claimants from class-action lawsuit in Paulsboro, New Jersey, who lived near a contamination

site, of 13 PFAS compounds tested, PFOS, PFOA, PFNA and PFHxS had the highest

prevalence, with over 70% with detectable levels [24]. This held true in other states, such as the

communities tested near military bases in Pennsylvania [45] where PFOS, PFOA, PFHxS, and

360 PFNA were highest and most prevalent of the 11 PFAS tested, and those in the Annison

361 Community Health Survey living near a high-risk manufacturing site in Alabama, where among

the 8 PFAS tested, PFOS, PFNA, PFOA, and PFHxS were detected in >96% [26].

363

Geometric means and trends cross demographic strata and percentiles among SHOW were like 364 those seen in NHANES. Yet, NHANES consistently had slightly higher geometric means for all 365 6 main PFAS compounds analyzed (PFOS, PFOA, PFNA, PFDA, PFHxS, PFHPS), even though 366 367 only PFHPS, PFDA, and PFNA were statistically significantly different at 0.05 level. While we are unsure why this is the case, it may be that Wisconsin has less exposure to PFAS in the 368 environment and/or in products used by its residents. PFOS was among the most prevalent of the 369 PFAS compounds measured among the SHOW sample and had the highest geometric mean and 370 371 percentile concentrations. This was also true among NHANES, as was seen among nearly all

372 prior biomonitoring studies, including those who tested high-risk populations such as firefighters

and communities near contamination sites [24-26,46,47]. Higher serum concentrations levels of

PFOS are not surprising due its (and PFOA's) U.S. production since the 1940s, which peaked

- between 1970 and 2002. PFOS and PFOA were the most widely used PFAS compounds inconsumer products up until recently [10].
- 377

378 Males and older age were associated with higher levels of PFAS in SHOW across all PFAS 379 compounds analyzed, with few exceptions. This trend held true in NHANES, and in other studies. For example, communities tested near military bases in Pennsylvania [45] found PFOS, 380 PFOA, and PFHxS were all higher in males, and all increased with age. Those tested living 381 382 nearby a PFAS manufacturing facility in New Jersey saw similar increases in PFAS concentration with age and were higher among males [24]. Olsen et al. similarly found sex and 383 age trends as seen in NHANES [48]. Lower concentrations in females may be explained by 384 greater excretion rate through menstrual blood loss and lactation [49]. We would expect PFAS 385 concentrations to be higher among older adults compared to younger adults due to the 386 bioaccumulation that occurs as one ages, in conjunction with potentially higher exposure >10

bioaccumulation that occurs as one ages, in conjunction with potentially higher exposure >10
 years ago before PFAS started being manufactured oversees and phased out of products.

389

Both SHOW and NHANES saw similar trends in PFAS concentrations by race, with non-

Hispanic whites having higher geometrics means compared to non-whites. While in SHOW, this

trend remained across percentiles, the NHANES sample saw opposite trends at the 90th and 95th

percentile for some compounds (PFHPS, PFDA, PFNA, PFOS), where non-whites had higher
 PFAS concentrations than non-Hispanic whites. This difference may be due to the small non-

white sample in SHOW and therefore an inability to adequately capture potential racial

differences in exposure and risk. Non-whites only account for 18.7% of the SHOW sample,

compared with approximately 35% in each NHANES sample. While the SHOW study

398 oversampled non-whites in 2019, they did not conduct oversampling of non-whites during their

statewide sampling years (2014-2016) used in this study. Due to Wisconsin's proportionately

small non-white population, the non-white sample in the SHOW study sample is small. This

401 likely resulted in little variability within the non-white subpopulation which may have resulted in

402 an unrepresentative substratum of non-whites in the state. As such, those who were included are 403 weighted to represent a larger proportion of their racial/ethnic subpopulation. Racial and ethnic

404 minorities, and those of lower socio-economic and education attainment, are more likely to

reside near industrial and contamination sites that are at greater risk of exposure to

406 environmental contaminants of concern, such as PFAS. This was seen in biomonitoring of a

407 high-risk community due to manufacturing in Alabama where PFOS levels were ~2 times higher

in African Americans compared to whites in the study [26]. We would expect a similar trend in

- 409 SHOW, but additional testing or sampling is needed.
- 410

411 The SHOW's relatively small substratum of non-whites was a limitation of the study. This may

412 have resulted in a less balanced comparison to NHANES and limited the study's ability to

identify racial disparities relating to PFAS that may exist in Wisconsin. While race may be an

414 important predictor of PFAS exposure, there are other demographic differences between SHOW

and NHANES that may have contributed to differences in the comparison of results. On average,

416 SHOW participants had a slightly higher education level and income to poverty ratio than

417 NHANES participants in all sampling years. It is well-known that lower income status is

associated with increased adverse environmental exposures [50], which may have contributed to

the lower levels of PFAS in SHOW participants than may exist in the state's population. There isevidence that higher PFAS exposure is associated with lower educational attainment [46].

421

422 While the SHOW 2014-2016 sample is representative of the state, its primary sampling unit was 423 at the county level, and only 9 counties were represented. Selection criteria used for SHOW's sampling frame to ensure representation was based on socioeconomic status and population 424 425 density; geographical representation was not a factor. This is a significant limitation of the study as northern regions of the state, and more isolated areas, are not represented. Future PFAS 426 biomonitoring in the state should include oversampling of non-whites and geographical 427 428 representation to adequately capture varied land use throughout the state; ensuring unique areas in central sands regions and northeast areas with karst geology are included, due to potentially 429 vulnerable groundwater contamination. Additionally, data on education and smoking status were 430 431 unavailable for 18- and 19-year-olds for NHANES, so some demographic comparisons do not include these individuals. Lastly, this study was cross-sectional, with serum concentrations from 432 over 6 years ago. Hence, not only can causality not be inferred, but changes over time are not 433 434 captured, and current PFAS concentrations among the state's population today may be different 435 than seen in this study. Future PFAS biomonitoring in Wisconsin should consider repeat testing, especially as short chain PFAS become more widely used and long chain PFAS are phased out. 436 437 438 While this study has several limitations, it has many strengths. This is the first statewide representative cohort for which we have baseline PFAS serum concentrations. Studies-to-date 439 have conducted biomonitoring on specific cohorts (i.e. California Teachers Study), among high-440 risk occupational workers (Firefighters), or communities residing near a contamination site. 441 While Yu et al. conducted statewide biomonitoring, they relied convenience testing from clinical 442 and lab sera [44], whereas SHOW relied on probability sampling to produce a statewide 443 444 representative sample with weights. This study also tested a wider range of PFAS compounds with LLOD for many. This was an important contribution to the field and increased our 445 446 understanding of the extent other PFAS compounds are in the environment and in our bodies. 447 These data suggest that Wisconsin residents may not be disproportionately burdened by PFAS 448 contamination compared to the wider US population. More research is needed to determine the 449 450 extent of PFAS exposure in Wisconsin which ensures geographical variation and adequate oversampling of non-whites. This is the beginning of our understanding of PFAS exposure 451 among Wisconsin residents, but importantly, it offers a baseline prevalence of PFAS. Future 452 453 directions include utilizing the rich SHOW survey data to better characterize PFAS serum levels 454 based on diet, housing, and other factors. These findings can help state agencies in resource allocation for additional PFAS biomonitoring, and direct resources where most needed. 455 456 Additionally, residential address and residential history is known for SHOW participants, which increases the capacity to study cumulative exposure to PFAS through neighborhood-level 457 contextual factors like industrial sites and nearby land uses through the adult life course. Finally, 458 longitudinal follow-up should be conducted in the future to track changes in PFAS burden in the 459 population over time. 460

461

462 Data Availability Statement

- The datasets generated during and analyzed during the current study are not publicly available
- due to HIPAA protections for SHOW participants but may be available from the corresponding
- author on reasonable request with IRB approval.
- 466

467 Acknowledgements

- 468 The authors would like to thank all the SHOW investigators who made this work possible,
- 469 WSLH staff who contributed to the creation of this data, and the SHOW participants.
- 470

471 Author Contributions

- 472 Conceptualization: A.S., N.S., K.M.; Methodology: N.S., M.L., A.S., Sample Analysis: N.S.,
- 473 M.L., Data Analysis: A.S., R.P.; Draft Preparation: A.S., R.P., N.S., K.M.; Review and Editing:
- 474 A.S., R.P., R.I., J.M., K.M.; Supervision: K.M., N.S.; Funding Acquisition: A.S., N.S.

475 476 **Funding**

- Funding for SHOW comes from the Wisconsin Division of Public Health, the Wisconsin
- 478 Partnership Program (PERC) Award (223 PRJ 25DJ), the National Institutes of Health's Clinical
- and Translational Science Award (5UL 1RR025011), and the National Heart Lunch and Blood
- 480 Institute (1 RC2 HL101468) and a core grant to the Center for Demography and Ecology at the
- 481 University of Wisconsin-Madison (P2C HD047873).
- 482

483 Ethical Approval

- 484 The SHOW protocol and informed consent documents are approved by the Health Sciences
- Institutional Review Board of the University of Wisconsin-Madison. Participants in SHOW
- 486 gave consent to their information being used for research prior to this study.
- 487

488 **Competing Interests**

- 489 The authors declare no competing interests related to this work.
- 490

491 Tables and Figures

492

Table 1.

Demographics characteristics of SHOW 2014-2016 compared with NHANES 2015-2016, and NHANES 2017-2018 cohorts.

	SHOW 2014-2016			NH	NHANES 2015-2016			NHANES 2017-2018		
		(n =60	5)		(n= 182	9)		(n=1862	2)	
	n	Column % ^a	95% CI (%)	n	Column % ^b	95% CI (%)	n	Column % ^b	95% CI	
Gender										
Male	257	49.3	44.8,53.8	865	48.4	45.1,51.6	922	48.5	45.1,52.0	
Female	346	50.7	46.2,55.2	964	51.6	48.4,54.9	940	51.5	48.0,54.9	
Age (in years)										
18-39	162	36.0	31.5,40.6	674	37.6	34.6,40.7	641	38.5	35.2,41.8	
40-59	208	36.4	32.1,40.7	581	35.1	31.8,38.3	558	33.4	29.9,36.9	
60-94	233	27.6	24.1,31.2	574	27.3	24.4,30.2	663	28.1	25.1,31.0	
Race										
White (non- Hispanic)	502	81.3	77.5,85.0	563	62.9	60.2,65.7	644	62.3	59.4,65.3	
Non-white	100	18.7	15.0,22.5	1266	37.1	34.3,39.8	1218	37.7	34.7,40.6	
Education*										
H.S./GED or less	151	27.1	23.0,30.5	778	34.2	31.3,37.2	771	38.2	34.9,41.6	
Some college	217	36.1	31.8,40.4	547	34.8	31.6,37.9	574	30.1	27.0,33.1	
Bachelors or higher	235	36.8	32.6,41.1	424	31.0	27.8,34.2	415	31.7	28.1,35.3	
Income/Poverty										
Katio <1	44	14.0	10.7.17.3	395	21.0	18.7.23.2	351	22.6	20.1.25.2	
1-3	220	38.9	34.5.43.3	708	33.2	30.3.36.1	717	31.7	28.8.34.6	
>3	311	47.1	42.6.51.5	445	45.9	42.5.49.2	422	45.7	42.1.49.2	
Smoking Status*			,.			,			,	
Current	73	15.0	11.5,18.6	356	19.6	17.1,22.1	334	17.3	14.8,19.8	
Former	146	23.7	19.9,27.6	389	23.8	21.0,26.7	408	21.3	18.4,24.1	
Never	345	61.2	56.7,65.6	1081	56.6	53.3,59.8	1120	61.4	58.1,64.8	
BMI										
< 25	161	26.6	22.7,30.5	537	31.3	28.3,34.3	541	29.0	25.8,32.1	
25-30	200	31.4	27.3,35.4	548	29.4	26.4,32.3	577	31.5	28.2,34.8	
> 30	237	42.1	37.6,46.5	744	39.3	36.2,42.5	744	39.5	36.2,42.9	

^a SHOW sample weights used for statewide representation ^b NHANES sample weights used for national representation ^c Income/Poverty Ratio is calculated by dividing total family income by the poverty guidelines from the Department of Health and Human Services (HHS) for the number of people supported by that income. *18 and 19 year olds excluded from education and smoking data in NHANES sample Abbreviations: Met Min / wk - Metabolic minutes per week; H.S. – High School; G.E.D – General Education Diploma; BMI – Body Mass Index

493 Table 2. Summary of SHOW results for all PFAS analytes

HOW serum PFAS result mmary

605

Analyte	Abbreviation	CAS-RNb	Detection Limit	# positive SHOW results	% positive results	Weighted Geometric Mean	Min result	Max Result
rfluoro-n-butanesulfonic id	PFBS	375-73-5	0.022	78	12.8926	0.0708	0.022	0.158
orfluoropentanesulfonic id	PFPeS	2706-91-4	0.015	351	58.0165	0.074	0.015	0.523
rfluoro-n-hexanesulfonic id	PFHxS	355-46-4	0.028	599	99.0083	1.138	0.033	30
rfluoro-n-heptanesulfonic id	PFHpS	375-92-8	0.027	583	96.3636	0.168	0.027	2.58
rfluoro-n-octanesulfonic id	PFOS	1763-23-1	0.036	602	99.5041	4.513	0.056	32.9
rfluorononanesulfonic id	PFNS	68259-12-1	0.018	1	0.16529	0.071	0.021	0.021
rfluoro-n-decanesulfonic id	PFDS	335-77-3	0.049	16	2.64463	0.071	0.05	0.188
rfluorooctanesulfonamide	FOSA	754-91-6	0.029	1	0.16529	0.071	0.055	0.055
methyl rfluorooctanesulfonamide	NMeFOSA	31506-32-8	0.246	0	0	N/A	N/A	N/A
ethyl rfluorooctanesulfonamide	NEtFOSA	4151-50-2	0.064	3	0.5	0.071	0.085	0.102
methyl rfluorooctanesulfonamido etic acid	NMeFOSAA	2355-31-9	0.145	294	48.6	0.137	0.147	2.8
ethyl rfluorooctanesulfonamido etic acid	NEtFOSAA	2991-50-6	0.184	13	2.15	0.073	0.195	2.02
Methyl rfluorooctanesulfonamido nanol	N-MeFOSE	24448-09-7	0.099	1	0.17	0.071	0.128	0.128
rfluorooctanesulfonamido	N-EtFOSE	1691-99-2	0.139	0	0	N/A	N/A	N/A
2 Fluorotelomer sulfonic id	4:2 FTSA	757124-72- 4	0.067	50	8.26	0.072	0.066	0.151
2 Fluorotelomer sulfonic id	6:2 FTSA	27619-97-2	0.149	0	0	N/A	N/A	N/A
2 Fluorotelomer sulfonic id	8:2 FTSA	39108-34-4	0.101	26	4.3	0.072	0.102	0.227
2 Fluorotelomer sulfonic id	10:2 FTSA	120226-60- 0	0.081	33	5.45	0.071	0.082	0.122
Chlorohexadecafluoro-3- anonane-1-sulfonic acid	9Cl-PF3ONS	756426-58- 1	0.009	252	41.65	0.071	0.009	0.293
erfluoro-n-butanoic acid	PFBA	375-22-4	0.039	173	28.6	0.074	0.039	0.546
rfluoro-n-pentanoic acid	PFPeA	2706-90-3	0.015	39	6.45	0.072	0.016	1.11

rfluoro-n-hexanoic acid	PFHxA	307-24-4	0.043	2	0.33	0.071	0.046	0.071
rfluoro-n-heptanoic acid	PFHpA	375-85-9	0.031	352	58.18	0.075	0.031	2.85
rfluoro-n-octanoic acid	PFOA	335-67-1	0.025	603	99.67	1.196	0.038	19.1
rfluoro-n-nonanoic acid	PFNA	375-95-1	0.021	601	99.34	0.452	0.022	12
rfluoro-n-decanoic acid	PFDA	335-76-2	0.024	598	98.84	0.142	0.024	4.51
rfluoro-n-undecanoic acid	PFUnDA	2058-94-8	0.042	460	76.03	0.094	0.042	1.36
rfluoro-n-dodecanoic acid	PFDoA	307-55-1	0.053	23	3.8	0.071	0.057	0.295
rfluoro-n-tridecanoic acid	PFTriA	72629-94-8	0.391	0	0	N/A	N/A	N/A
rfluoro-n-tetradecanoic id	PFTeA	376-06-7	0.032	2	0.33	0.071	0.035	0.041
rfluoro-n-hexadecanoic id	PFHxDA	67905-19-5	0.085	1	0.17	0.071	0.097	0.097
rfluoro-n-octadecanoic id	PFODA	16517-11-6	0.164	0	0	N/A	N/A	N/A
8-Dioxa-3H- rfluorononanoic acid	DONA	919005-14- 4	0.012	0	0	N/A	N/A	N/A
-chloroeicosafluoro-3- aundecane-1-sulfonic id	11Cl- PF3OUdS	763051-92- 9	0.011	2	0.33	0.071	0.13	0.14
2 di-subs. polyfluoroalkyl osphate.	6:2 diPAP	57677-95- 9	0.077	23	3.8	0.073	0.078	0.451
2 di-subs. polyfluoroalkyl osphate.	8:2 diPAP	678-41-1	0.134	3	0.5	0.071	0.254	0.296
erfluoro-2- ethoxypropanoic acid.	PFMPA	377-73-1	0.019	0	0	N/A	N/A	N/A
erfluoro-2- ethoxybutanoic acid.	PFMBA	863090- 89-5	0.017	0	0	N/A	N/A	N/A

ghlighted rows indicate inclusion in both SHOW and NHANES analyses. Compounds with percentages of positive results less than 15% SHOW were not included in comparisons as we are unable to draw reliable conclusions

494

Table 3. Geometric Means and Percentile Comparisons between SHOW and NHANES

		n	Geometric mean (95% CI)	50th (95% CI)	75th (95% CI)	90th (95% CI)	95th (95% CI)	p-trend
PFOS	SHOW	605	4.51 (4.18 - 4.87)	5.01 (4.54 - 5.49)	8.19 (7.53 - 8.85)	11.28 (10.61 - 12.43)	14.97(13.32 - 16.77)	0.54
	NHANES	1829	4.97 (4.71 - 5.25)	5.20 (4.80- 5.40)	8.60 (8.00- 9.40)	13.80 (12.90- 15.40)	19.00 (16.80- 21.50)	
PFOA	SHOW	605	1.20 (1.12 - 1.27)	1.30 (1.20 - 1.40)	1.90 (1.80 - 1.90)	2.60 (2.40 - 2.90)	3.30 (2.90 - 3.50)	<0.0001

				1.60	2.50	3.40		
			1.59 (1.52	(1.50-	(2.20-	(3.20-	4.20 (3.80-	
	NHANES	1829	- 1.67)	1.70)	2.50)	3.60)	4.70)	
			0.45	0.50	0.70	1.00		
			(0.43-	(0.40 -	(0.60 -	(0.90 -	1.40 (1.20 -	
PFNA	SHOW	605	0.48)	0.50)	0.70)	1.20)	1.70)	< 0.0001
			0.59	0.50	0.90	1.40		
			(0.56-	(0.40-	(0.80-	(1.20-	1.90 (1.50-	
	NHANES	1829	0.62)	0.50)	0.90)	1.40)	2.10)	
			1.14	1.30	2.10	3.30		
			(1.04-	(1.20 -	(1.80 -	(3.00 -	4.60 (4.00 -	
PFHxS	SHOW	605	1.24)	1.40)	2.30)	4.00)	5.60)	0.58
			1.22	1.20	2.10	3.40		
			(1.15-	(1.10-	(1.90-	(3.20-	5.00 (4.10-	
	NHANES	1829	1.29)	1.30)	2.20)	3.80)	5.80)	
			0.14	0.10	0.20	0.30		
			(0.13-	(0.10 -	(0.20-	(0.30-	0.50 (0.40-	
PFDA	SHOW	605	0.15)	0.20)	0.20)	0.40)	0.60)	0.023
			0.16	0.10	0.20	0.40		
			(0.15-	(0.10-	(0.20-	(0.30-	0.70 (0.50-	
	NHANES	1829	0.17)	0.10)	0.20)	0.40)	0.70)	
			0.17	0.17	0.28	0.37		
			(0.16-	(0.16-	(0.26-	(0.35-	0.46 (0.42-	
PFHPS	SHOW	605	0.18)	0.19)	0.30)	0.40)	0.49)	< 0.0001
			0.23	0.19	0.34	0.60		
			(0.22-	(0.090-	(0.28-	(0.50-	0.95 (0.69-	
	NHANES	2133	0.25)	0.19)	0.34)	0.60)	1.40)	

495

Table 4. Geometric means and percentiles of serum PFOS by demographic characteristcs- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

PFOS		n	Geometric mean (95% CI)	50th (95% CI)	75th (95% CI)	90th (95% CI)	95th (95% CI)
	Age						
			3.13	3.70	5.50		
			(2.71-	(3.30-	(4.60-	7.60 (6.30-	8.80 (7.70-
SHOW	18-39	162	3.62)	4.10)	6.20)	8.80)	10.20)
			3.49	3.60	5.90		11.30
			(3.20-	(3.20-	(5.30-	9.50 (8.20-	(10.40-
NHANES	18-39	674	3.79)	3.80)	6.50)	10.60)	14.10)

SHOW	40-59	208	4.46 (3.97- 5.00)	4.90 (4.20- 5.50)	8.20 (7.00- 9.10)	10.80 (9.60- 12.30)	12.60 (11.10- 16.50)
NHANES	40-59	581	5.20 (4.77- 5.66)	5.30 (4.60- 5.70)	8.20 (7.10- 9.70)	13.60 (11.40- 16.00)	17.40 (15.70- 22.60)
SHOW	60+	233	7.39 (6.72- 8.312)	7.80 (7.20- 8.70)	11.20 (10.40- 12.80)	16.60 (14.10- 18.70)	19.70 (17.20- 25.30)
NHANES	60+	574	7.56 (6.83- 8.37)	7.90 (7.10- 8.50)	12.70 (11.10- 13.60)	19.10 (16.70- 22.10)	26.30 (21.80- 30.50)
	Sex						
SHOW	Male	257	5.08 (4.49- 5.74)	5.70 (5.20- 6.40)	8.90 (8.20- 9.30)	12.20 (10.70- 14.30)	16.40 (13.60- 18.50)
NHANES	Male	865	6.59 (6.16- 7.05)	6.60 (6.00- 7.10)	10.40 (9.60- 11.10)	16.10 (14.10- 18.90)	22.00 (19.00- 24.50)
SHOW	Female	346	4.02 (3.67- 4.41)	4.10 (3.70- 4.60)	7.20 (6.40- 8.00)	10.90 (9.70- 12.20)	13.60 (11.60- 16.40)
NHANES	Female	964	3.81 (3.53- 4.12)	3.80 (3.40- 4.10)	6.50 (5.90- 7.20)	11.10 (10.20- 12.60)	15.80 (13.20- 17.80)
	Race						
SHOW	White (Non- Hispanic)	502	4.91 (4.54- 5.31)	5.45 (4.92- 5.87)	8.50 (7.82- 9.10)	12.14 (11.02- 13.46)	15.59 (13.49- 16.81)
NHANES	White (Non- Hispanic)	563	5.16 (4.77- 5.58)	5.30 (4.74- 5.62)	9.03 (7.90- 10.17)	13.41 (12.30- 15.88)	17.64 (15.97- 21.94)
SHOW	Non- White	100	3.16 (2.55- 3.91)	3.57 (2.93- 4.19)	5.75 (4.43- 8.03)	9.25 (7.66- 11.06)	10.48 (8.75- 18.06)
NHANES	Non- White	1266	4.65 (4.38- 4.95)	4.73 (4.40- 5.10)	8.34 (7.74- 8.85)	14.51 (12.99- 15.99)	21.79 (18.29- 23.54)

496

Table 5. Geometric means and percentiles of serum PFOA by demographic characteristics- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

			Geometric mean (95%	50th (95%	75th (95%	90th (95%	95th (95%
PFOA		n	CI)	CI)	CI)	CI)	CI)
	Age						
SHOW	18-39	162	0.93 (0.82- 1.05)	1.10 (0.90- 1.20)	1.60 (1.40- 1.80)	2.00 (1.90- 2.30)	2.40 (2.00- 3.20)
NHANES	18-39	674	1.31 (1.21- 1.40)	1.40 (1.20- 1.40)	2.00 (1.80- 2.20)	2.80 (2.50- 3.00)	3.50 (2.90- 3.90)
SHOW	40-59	208	1.28 (1.16- 1.41)	1.30 (1.20- 1.50)	1.80 (1.70- 2.10)	2.60 (2.40- 3.10)	3.30 (2.70- 4.60)
NHANES	40-59	581	1.64 (1.53- 1.77)	1.60 (1.40- 1.80)	2.40 (2.10- 2.50)	3.30 (3.10- 3.60)	3.90 (3.50- 5.20)
SHOW	60+	233	1.51 (1.38- 1.65)	1.50 (1.40- 1.80)	2.30 (2.10- 2.50)	3.30 (2.80- 3.50)	3.50 (3.40- 4.20)
NHANES	60+	574	2.01 (1.81- 2.22)	2.10 (1.90- 2.20)	2.80 (2.60- 3.10)	4.20 (3.60- 4.90)	5.20 (4.60- 6.90)
	Sex						
SHOW	Male	257	1.25 (1.13- 1.37)	1.40 (1.30- 1.50)	1.90 (1.80- 2.00)	2.60 (2.40- 3.00)	3.20 (2.90- 3.60)
NHANES	Male	865	1.85 (1.75- 1.96)	1.90 (1.70- 2.00)	2.60 (2.50- 2.70)	3.40 (3.20- 3.60)	4.10 (3.60- 5.010)
SHOW	Female	346	1.15 (1.06- 1.25)	1.20 (1.10- 1.20)	1.80 (1.70- 2.00)	2.70 (2.40- 3.10)	3.50 (2.90- 4.20)
NHANES	Female	964	1.39 (1.29- 1.49)	1.40 (1.30- 1.50)	2.30 (2.00- 2.40)	3.40 (2.90- 3.90)	4.30 (3.90- 6.10)
	Race						
SHOW	White (Non- Hispanic)	502	1.28 (1.20- 1.37)	1.40 (1.30- 1.50)	1.90 (1.80- 2.00)	2.80 (2.50- 3.10)	3.40 (3.10- 4.00)

NHANES	White (Non- Hispanic)	563	1.72 (1.60- 1.84)	1.80 (1.60- 1.90)	2.60 (2.40- 2.70)	3.50 (3.20- 3.80)	4.60 (3.90- 5.60)
SHOW	Non- White	100	0.90 (0.77- 1.05)	1.00 (0.80- 1.10)	1.40 (1.20- 1.80)	2.00 (1.60- 2.50)	2.40 (2.00- 3.00)
NHANES	Non- White	1266	1.40 (1.34- 1.47)	1.40 (1.30- 1.40)	2.10 (2.00- 2.20)	3.10 (2.80- 3.30)	4.00 (3.60- 4.10)

497

Table 6. Geometric means and percentiles of serum PFNA by demographic characteristcs- comparing 18+ in SHOW 2014-2016 with U.S. NHANES 2015-2016

DENIA		n	Geometric mean (95%	50th (95%	75th (95%	90th (95%	95th (95%
FFNA	•	11	CI)	CI)			
	Age						
SHOW	18-39	162	0.36 (0.32- 0.41)	0.40 (0.30- 0.40)	0.60 (0.50- 0.70)	0.80 (0.70- 1.10)	1.10 (0.80- 1.40)
NHANES	18-39	674	0.46 (0.43- 0.50)	0.40 (0.30- 0.40)	0.70 (0.60- 0.70)	1.00 (0.90- 1.00)	1.30 (1.10- 1.50)
SHOW	40-59	208	0.44 (0.40- 0.48)	0.40 (0.40- 0.50)	0.60 (0.60- 0.70)	0.90 (0.80- 1.20)	1.30 (1.00- 1.70)
NHANES	40-59	581	0.60 (0.55- 0.66)	0.50 (0.50- 0.60)	0.90 (0.80- 1.00)	1.30 (1.20- 1.50)	1.90 (1.40- 2.30)
SHOW	60+	233	0.62 (0.56- 0.67)	0.60 (0.60- 0.70)	0.90 (0.80- 0.90)	1.40 (1.20- 1.80)	2.10 (1.50- 2.60)
NHANES	60+	574	0.78 (0.71- 0.85)	0.70 (0.60- 0.80)	1.10 (1.00- 1.30)	1.70 (1.50- 2.00)	2.30 (1.90- 2.60)
	Sex						
SHOW	Male	257	0.47 (0.43- 0.51)	0.50 (0.40- 0.50)	0.70 (0.60- 0.80)	1.00 (0.90- 1.20)	1.40 (1.10- 2.10)
NHANES	Male	865	0.64 (0.60- 0.69)	0.50 (0.40- 0.50)	0.90 (0.80- 1.00)	1.40 (1.10- 1.40)	1.90 (1.50- 2.10)

SHOW	Female	346	0.44 (0.40- 0.48)	0.40 (0.40- 0.50)	0.70 (0.60- 0.80)	1.10 (0.90- 1.30)	1.40 (1.20- 2.00)
NHANES	Female	964	0.54 (0.50- 0.58)	0.40 (0.30- 0.40)	0.80 (0.70- 0.80)	1.30 (1.10- 1.40)	1.90 (1.40- 2.40)
	Race						
SHOW	White (Non- Hispanic)	502	0.48 (0.45- 0.51)	0.50 (0.40- 0.50)	0.70 (0.70- 0.80)	1.10 (0.90- 1.30)	1.50 (1.30- 2.10)
NHANES	White (Non- Hispanic)	563	0.58 (0.54- 0.62)	0.50 (0.40- 0.50)	0.90 (0.70- 0.90)	1.30 (1.10- 1.40)	1.90 (1.40- 2.30)
SHOW	Non- White	100	0.36 (0.31- 0.41)	0.30 (0.30- 0.40)	0.60 (0.50- 0.70)	0.80 (0.60- 1.10)	1.00 (0.80- 1.50)
NHANES	Non- White	1266	0.60 (0.57- 0.63)	0.50 (0.40- 0.50)	0.90 (0.80- 1.00)	1.40 (1.30- 1.50)	1.90 (1.60- 2.00)

498 499

500 501	Bibliography
502 503	1 Ghisi R, Vamerali T, Manzetti S. Accumulation of perfluorinated alkyl substances (PFAS) in agricultural plants: A Review. Environmental Research. 2019;169:326–41.
504 505 506 507	2 Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (pfass) and present understanding of health effects. Journal of Exposure Science & Environmental Epidemiology. 2018;29(2):131–47.
508 509 510	3 Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per- and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea Food web. Environmental Pollution. 2007;148(1):360–71.
511	4 Faithfull NS, Weers JG. Perfluorocarbon compounds. Vox Sanguinis. 1998;74(S2):243-8.
512 513 514 515	5 Hu XC, Andrews DQ, Lindstrom AB, Bruton TA, Schaider LA, Grandjean P, et al. Detection of poly- and perfluoroalkyl substances (pfass) in U.S. drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environmental Science & Technology Letters. 2016;3(10):344–50.
516 517 518	6 Kurwadkar S, Dane J, Kanel SR, Nadagouda MN, Cawdrey RW, Ambade B, et al. Per- and polyfluoroalkyl substances in water and wastewater: A critical review of their global occurrence and distribution. Science of The Total Environment. 2022;809:151003.
519 520	7 Sinclair GM, Long SM, Jones OAH. What are the effects of PFAS exposure at environmentally relevant concentrations? Chemosphere. 2020;258:127340.
521 522 523	8 Per- and polyfluorinated substances (PFAS) factsheet [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2022 [cited 2023Jan17]. Available from: https://www.cdc.gov/biomonitoring/PFAS_FactSheet.html
524 525 526	9 Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, et al. Per□ and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Environmental Toxicology and Chemistry. 2020;40(3):606–30.
527 528	10 DeWitt JC. Toxicological effects of perfluoroalkyl and polyfluoroalkyl substances. Cham, New York: Springer International Publishing; 2015.
529 530 531	11 Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environmental Health Perspectives. 2010;118(2):197–202.

532 533 534	12 Bassler J, Ducatman A, Elliott M, Wen S, Wahlang B, Barnett J, et al. Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines. Environmental Pollution. 2019;247:1055–63.
535	13 Wikström S, Lin P-I, Lindh CH, Shu H, Bornehag C-G. Maternal serum levels of
536	perfluoroalkyl substances in early pregnancy and offspring birth weight. Pediatric
537	Research. 2019;87(6):1093–9.
538	14 von Holst H, Nayak P, Dembek Z, Buehler S, Echeverria D, Fallacara D, et al. Perfluoroalkyl
539	Substances Exposure and immunity, allergic response, infection, and asthma in children:
540	Review of Epidemiologic Studies. Heliyon. 2021;7(10).
541	15 Borghese MM, Walker M, Helewa ME, Fraser WD, Arbuckle TE. Association of
542	perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC
543	study. Environment International. 2020;141:105789.
544	16 Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, et al. Pre-natal
545	exposure to perfluoroalkyl substances may be associated with altered vaccine antibody
546	levels and immune-related health outcomes in early childhood. Journal of
547	Immunotoxicology. 2013;10(4):373–9.
548	17 Brennan NM, Evans AT, Fritz MK, Peak SA, von Holst HE. Trends in the regulation of per-
549	and polyfluoroalkyl substances (PFAS): A scoping review. International Journal of
550	Environmental Research and Public Health. 2021;18(20):10900.
551	18 Chen J, Tang L, Chen W-Q, Peaslee GF, Jiang D. Flows, stock, and emissions of poly- and
552	perfluoroalkyl substances in California carpet in 2000–2030 under different scenarios.
553	Environmental Science & Technology. 2020;54(11):6908–18.
554 555 556 557	19 Podder A, Sadmani AHMA, Reinhart D, Chang N-B, Goel R. Per and poly-fluoroalkyl substances (PFAS) as a contaminant of emerging concern in Surface Water: A transboundary review of their occurrences and toxicity effects. Journal of Hazardous Materials. 2021;419:126361.
558 559	20 US EPA. Lifetime Drinking Water Health Advisories for Four Perfluoroalkyl Substances. 2022; 87 FRL 9855–01–OW. (To be codified and 87 C.F.R. pts. 36848, 36849).
560 561 562	21 Kidd J, Fabricatore E, Jackson D. Current and future federal and state sampling guidance for per- and polyfluoroalkyl substances in environmental matrices. Science of The Total Environment. 2022;836:155523.
563 564	22 Birnbaum LS, Grandjean P. Alternatives to pfass: Perspectives on the science. Environmental Health Perspectives. 2015;123(5).

- 23 Aylward LL, Seiber JN, Hays SM. California biomonitoring data: Comparison to NHANES
 and interpretation in a risk assessment context. Regulatory Toxicology and Pharmacology.
 2015;73(3):875–84.
- 24 Graber JM, Alexander C, Laumbach RJ, Black K, Strickland PO, Georgopoulos PG, et al. Per
 and polyfluoroalkyl substances (PFAS) blood levels after contamination of a community
 water supply and comparison with 2013–2014 NHANES. Journal of Exposure Science &
 Environmental Epidemiology. 2018;29(2):172–82.
- 572 25 Graber JM, Black TM, Shah NN, Caban-Martinez AJ, Lu S-en, Brancard T, et al. Prevalence
 573 and predictors of per- and polyfluoroalkyl substances (PFAS) serum levels among
 574 members of a suburban US volunteer fire department. International Journal of
 575 Environmental Research and Public Health. 2021;18(7):3730.
- 26 Petriello MC, Mottaleb MA, Serio TC, Balyan B, Cave MC, Pavuk M, et al. Serum
 concentrations of legacy and emerging per- and polyfluoroalkyl substances in the Anniston
 Community Health Surveys (ACHS I and ACHS II). Environment International.
 2022;158:106907.
- 27 Yu CH, Weisel CP, Alimokhtari S, Georgopoulos PG, Fan Z(T. Biomonitoring: A tool to
 assess PFNA body burdens and evaluate the effectiveness of drinking water intervention
 for communities in New Jersey. International Journal of Hygiene and Environmental
 Health. 2021;235:113757.
- 28 Multiple state agencies responding to PFAS contamination on French Island [Internet].
- 585 Wisconsin Department of Natural Resources. Wisconsin Department of Natural Resources;
- 586 2021 [cited 2023Jan17]. Available from:
- 587 https://dnr.wisconsin.gov/newsroom/release/42441
- 29 Pfas contamination in the Marinette and Peshtigo Area [Internet]. PFAS Contamination in the
 Marinette and Peshtigo Area || Wisconsin DNR. Wisconsin Department of Natural
- 590 Resources: 2022 [cited 2023Jan17]. Available from:
- 591 https://dnr.wisconsin.gov/topic/PFAS/Marinette.html
- 30 Ankley GT, Lodge K, Call DJ, Balcer MD, Brooke LT, Cook PM, et al. Integrated
 assessment of contaminated sediments in the Lower Fox River and Green Bay, Wisconsin.
 Ecotoxicology and Environmental Safety. 1992;23(1):46–63.
- 31 Imamoglu I, Christensen ER. PCB sources, transformations, and contributions in recent Fox
 River, Wisconsin sediments determined from receptor modeling. Water Research.
 2002;36(14):3449–62.
- Sullivan JR, Delfino JJ, Buelow CR, Sheffy TB. Polychlorinated biphenyls in the fish and
 sediment of the Lower Fox River, Wisconsin. Bulletin of Environmental Contamination
 and Toxicology. 1983;30(1):58–64.

601	33 Jha G, Kankarla V, McLennon E, Pal S, Sihi D, Dari B, et al. Per- and polyfluoroalkyl
602	substances (PFAS) in integrated crop–livestock systems: Environmental exposure and
603	human health risks. International Journal of Environmental Research and Public Health.
604	2021;18(23):12550.
605	34 Johnson GR. Pfas in soil and groundwater following historical land application of Biosolids.
606	Water Research. 2022;211:118035.
607	35 Water utility [Internet]. City of Madison, Wisconsin. [cited 2023Jan17]. Available from:
608	https://www.cityofmadison.com/water/water-quality/water-quality-testing/perfluorinated-
609	compounds
610	36 Staff AC. Wisconsin population increased 3.6% since 2010 [Internet]. Census.gov. United
611	States Census Bureau; 2021 [cited 2023Jan17]. Available from:
612	https://www.census.gov/library/stories/state-by-state/wisconsin-population-change-
613	between-census-decade.html
614	37 Malecki KM, Nikodemova M, Schultz AA, LeCaire TJ, Bersch AJ, Cadmus-Bertram L, et al.
615	The survey of the Health of Wisconsin (show) program: An infrastructure for advancing
616	population health. Frontiers in Public Health. 2022;10.
617	38 Minnesota Dept. of Public Health, Public Health Laboratory Division. Document DOC-563,
618	Detection of PFAS in serum and Plasma via LC-MS/MS. Unpublished methods.
619	39 Centers for Disease Control & Prevention, National Center for Environmental Health.
620	Laboratory Procedure manual NHANES 2015-16, method 6304.08. Perfluoroalkyl and
621	Polyfluoroalkyl Substances.
622	40 New York State Dept. of Health, Division of Environmental Health Sciences, Laboratory of
623	Organic Analytical Chemistry. Analysis of Perfluoroalkyl Substances In Human Serum by
624	Solid Phase Extraction and Ultra High Performance Liquid Chromatography Tandem Mass
625	Spectrometry. Unpublished methods.
626 627	41 Michigan Dept. of Community Health, Bureau of Laboratories. Document AC-54. Analysis of serum for PFAS by RP-HPLC-MRM-MS/MS. 2018. Unpublished methods.
628 629 630	42 Centers for Disease Control and Prevention. Nhanes - about the National Health and Nutrition Examination Survey. 2017. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm (accessed 2 May 2022).
631 632 633	43 Prior HHS Poverty Guidelines and Federal Register references [Internet]. ASPE. 2022 [cited 2023Jan17]. Available from: https://aspe.hhs.gov/topics/poverty-economic-mobility/poverty-guidelines/prior-hhs-poverty-guidelines-federal-register-references

634	 44 Yu CH, Riker CD, Lu S-en, Fan Z(T. Biomonitoring of emerging contaminants,
635	perfluoroalkyl and polyfluoroalkyl substances (PFAS), in New Jersey Adults in 2016–
636	2018. International Journal of Hygiene and Environmental Health. 2020;223(1):34–44.
637 638 639 640	45 Nair AS, Ma Z-qiang, Watkins SM, Wood SS. Demographic and exposure characteristics as predictors of serum per- and polyfluoroalkyl substances (pfass) levels – a community-level biomonitoring project in Pennsylvania. International Journal of Hygiene and Environmental Health. 2021;231:113631.
641	46 Sagiv SK, Rifas-Shiman SL, Webster TF, Mora AM, Harris MH, Calafat AM, et al.
642	Sociodemographic and perinatal predictors of early pregnancy per- and polyfluoroalkyl
643	substance (PFAS) concentrations. Environmental Science & Technology.
644	2015;49(19):11849–58.
645	47 Wattigney WA, Savadatti SS, Liu M, Pavuk M, Lewis-Michl E, Kannan K, et al.
646	Biomonitoring of per- and polyfluoroalkyl substances in minority angler communities in
647	Central New York State. Environmental Research. 2022;204:112309.
648	48 Olsen GW, Mair DC, Lange CC, Harrington LM, Church TR, Goldberg CL, et al. Per- and
649	polyfluoroalkyl substances (PFAS) in American Red Cross Adult Blood Donors, 2000–
650	2015. Environmental Research. 2017;157:87–95.
651	49 Ding N, Harlow SD, Batterman S, Mukherjee B, Park SK. Longitudinal trends in
652	perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from
653	1999 to 2011: The study of women's health across the nation. Environment International.
654	2020;135:105381.
655	50 Evans GW, Kantrowitz E. Socioeconomic status and health: The potential role of

656 environmental risk exposure. Annual Review of Public Health. 2002;23(1):303–31.